deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03100942

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome

Sponsor: Galapagos NV

Conditions Sjogren's Syndrome
Interventions Filgotinib Filgotinib placebo Lanraplenib Lanraplenib placebo Tirabrutinib Tirabrutinib placebo
Updated 25 times since 2017 Last updated: Oct 1, 2020 Started: May 1, 2017 Primary completion: Jan 10, 2019 Completion: Oct 2, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Sjogren's Syndrome, this trial is completed. The trial is conducted by Galapagos NV and has accumulated 25 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Nov 2019 · 6 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 20 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2020 — Nov 2020 [monthly]

    Completed PHASE2

  3. Nov 2019 — Feb 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. May 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  8. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  9. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  10. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  13. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  14. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  15. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  16. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  17. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  18. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  19. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  20. May 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Galapagos NV
  • Gilead Sciences
  • Ono Pharmaceutical Co. Ltd
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Barcelona, Spain , Beaumont, United States , Bethlehem, United States , Charlotte, United States , Chattanooga, United States , Chesapeake, United States , Clearwater, United States , Covina, United States , DeBary, United States and 42 more locations